Galmed Pharmaceuticals Ltd.
Business
Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on the development of Aramchol, a synthetic fatty acid–bile acid conjugate, as its core therapeutic program. Its main product candidate is Aramchol (including Aramchol meglumine), developed primarily for nonalcoholic steatohepatitis (NASH), fibrosis and investigational oncologic indications, with efforts to expand into cardiometabolic indications. The company operates research and development through subsidiaries that hold its intellectual property and conduct clinical programs. Galmed advances Aramchol through global clinical trials and academic and institutional collaborations across the U.S., Latin America, Europe, Israel and other markets.
Summary from filing dated 2025-04-02
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-10.31M |
| Total assets | $18.63M |
| Total liabilities | — |
| Stockholders' equity | $15.78M |
| Operating cash flow | $-6.32M |